COMPOSITIONS FOR DELIVERY OF REBOXETINE
Described herein are methods for the administration of reboxetine, or a pharmaceutically acceptable salt thereof, to a human being in need thereof, resulting in a first maximum plasma concentration and a second maximum plasma concentration, wherein the two maxima are separated by a time period of about 2 hours to about 6 hours.
1 - 20 . (canceled)
21 . A dosage form comprising about 4 to about 6 mg of reboxetine free base, or a molar equivalent amount of a salt form of reboxetine, and microcrystalline cellulose.
22 . The dosage form of claim 21 , further comprising hydroxypropyl methylcellulose.
23 . The dosage form of claim 21 , further comprising polyvinylpolypyrrolidone.
24 . The dosage form of claim 21 , further comprising silicone dioxide colloidal.
25 . The dosage form of claim 21 , further comprising about 0.1% to about 3% magnesium stearate by weight.
26 . The dosage form of claim 21 , further comprising hydroxypropyl methylcellulose, polyvinylpolypyrrolidone, silicone dioxide colloidal, and about 0.1% to about 3% magnesium stearate by weight.
27 . The dosage form of claim 21 , wherein the reboxetine is in the free base form.
28 . The dosage form of claim 21 , wherein the reboxetine is in a salt form.
29 . The dosage form of claim 21 , wherein the reboxetine is in the form of mesylate salt.
30 . The dosage form of claim 21 , wherein the dosage form is in the form of a pill, a tablet, a capsule, a caplet, or a cachou.
31 . The dosage form of claim 21 , wherein the dosage form further comprises a binder.
32 . The dosage form of claim 21 , wherein the dosage form further comprises a lubricant.
33 . The dosage form of claim 21 , wherein the dosage form further comprises an inert excipient.